跳到正文
原文
Adam Feuerstein ✡️· @adamfeuerstein · X·· 2 小时前精选AI 评分62
AI 导读

Sellas Life Sciences 表示,其试验性血液肿瘤免疫疗法 galinpepimut-S 在晚期急性髓系白血病患者中较标准治疗将死亡风险降低 41%,达到 III 期临床试验的主要目标。STAT 记者 Adam Feuerstein 称,这一结果改变了他此前对该疗法和公司的判断。

推荐理由

Sellas 的 galinpepimut-S 在晚期急性髓系白血病 III 期试验中达到主要终点,读者可据此了解该在研免疫疗法的关键数据。

正文

It looks like I was wrong about Sellas Life Sciences $SLS and its experimental blood cancer immunotherapy.

On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia – an outcome that achieved the main goal of a Phase 3 clinical trial, the company said.

Story here:
https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/

来源:Adam Feuerstein ✡️ · x.com